Potential sources of diagnostic pitfall and variants in FDG-PET/CT;Potenciales fuentes de error diagnóstico y variantes de la FDG-PET/TAC

Revista Espanola de Medicina Nuclear

Volumn 27, Issue 2, 2008, Pages 130-159

  Quirce Pisano, R ^a   Banzo Marraco, I ^a   Jimenez Bonilla J F ^a   Martinez Rodriguez I ^a   Sainz Esteban, A ^a   Carril Carril, J M ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Artefact; FDG; PET CT; Physiological findings

Indexed keywords

FLUORODEOXYGLUCOSE; TECHNETIUM 99M;

CANCER RADIOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ERROR; HUMAN; LESIONS AND DEFECTS; LUNG CANCER; REVIEW;

EID: 42549127476     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1157/13117196     Document Type: Article

References (112)

1. Cook GJ, Wegner EA, Fogelman I. Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging. Semin Nucl Med. 2004;34:122-33.
2. Bockisch A, Beyer T, Antoch G, Freudenberg LS, Kühl H, Debatin JF, et al. Positron emission tomography/computed tomography-imaging protocols, artifacts, and pitfalls. Mol Imaging Biol. 2004;6:188-99.
3. Gorospe L, Raman S, Echeveste J, Avril N, Herrero Y, Herna Ndez S. Whole-body PET/CT: spectrum of physiological variants, artifacts and interpretative pitfalls in cancer patients. Nucl Med Commun. 2005;26:671-87.
4. Sureshbabu W, Mawlawi O. PET/CT imaging artifacts. J Nucl Med Technol. 2005;33:156-61.
5. Truong MT, Erasmus JJ, Macapinlac HA, Marom EM, Mawlawi O, Gladish GW, et al. Integrated positron emission tomography/ computed tomography in patients with non-small cell lung cancer: normal variants and pitfalls. J Comput Assist Tomogr. 2005;29:205-9.
6. Mawlawi O, Pan T, Macapinlac HA. PET/CT imaging techniques, considerations, and artifacts. J Thorac Imaging. 2006;21:99-110.
7. Rosenbaum SJ, Lind T, Antoch G, Bockisch A. False-positive FDG PET uptake-the role of PET/CT. Eur Radiol. 2006;16:1054-65.
8. Cook GJ. Pitfalls in positron emission tomography/computed tomography interpretation. Q J Nucl Med Mol Imaging. 2007;51:235-43.
9. Torizuka T, Clavo AC, Wahl RL. Effect of hyperglycemia on in vitro tumor uptake of tritiated FDG, thymidine, L-methionine and L-leucine. J Nucl Med. 1997;38:382-6.
10. Torizuka T, Fisher SJ, Whal RL. Insulin induced hypoglycaemia decreases uptake of 2-[-18] fluoro-2-deoxy-D-glucose into experimental mammary carcinoma. Radiology. 1997;203:169-72.
11. Plantade A, Montravers F, Selle F, Izrael V, Talbot JN. Diffusely increased F-18 FDG uptake in bone marrow in a patient with acute anemia and recent erythropoietin therapy. Clin Nucl Med. 2003;28:771-2.
12. Kazama T, Swanston N, Podoloff DA, Macapinlac HA. Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow. Eur J Nucl Med Mol Imaging. 2005;32:1406-11.
13. Kostakoglu L, Wong JC, Barrington SF, Cronin BF, Dynes AM, Maisey MN. Speech-related visualization of laryngeal muscles with fluorine-18-FDG. J Nucl Med. 1996;37:1771-3.
14. Tashiro M, Fujimoto T, Itoh M, Kubota K, Fujiwara T, Miyake M, et al. 18F-FDG PET imaging of muscle activity in runners. J Nucl Med. 1999;40:70-6.
15. Barrington SF, Maisey MN. Skeletal muscle uptake of fluorine-18-FDG: effect of oral diazepam. J Nucl Med. 1996;37:1127-9.
16. Basu S, Alzeair S, Li G, Dadparvar S, Alavi A. Etiopathologies associated with intercostal muscle hypermetabolism and prominent right ventricle visualization on 2-deoxy-2[F-18]fluoro-D-glucose-positron emission tomography: significance of an incidental finding and in the setting of a known pulmonary disease. Mol Imaging Biol. 2007;9:333-9.
17. Hany TF, Gharehpapagh E, Kamel EM, Buck A, Himms-Hagen J, von Schulthess GK. Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region. Eur J Nucl Med Mol Imaging. 2002;29:1393-8.
18. Ferdinand B, Gupta P, Kramer EL. Spectrum of thymic uptake at 18F-FDG PET. Radiographics. 2004;24:1611-6.
19. Nakamoto Y, Tatsumi M, Hammoud D, Cohade C, Osman MM, Wahl RL. Normal FDG distribution patterns in the head and neck: PET/CT evaluation. Radiology. 2005;234:879-85.
20. Choi Y, Brunken RC, Hawkins RA, Huang SC, Buxton DB, Hoh CK, et al. Factors affecting myocardial 2-[F-18]fluoro-2-deoxy-D-glucose uptake in positron emission tomography studies of normal humans. Eur J Nucl Med. 1993;20:308-18.
21. Dunphy MP, Freiman A, Larson SM, Strauss HW. Association of vascular 18F-FDG uptake with vascular calcification. J Nucl Med. 2005;46:1278-84.
22. Imperiale A, Cimarelli S, Sellem DB, Blondet C, Contantinesco A. Focal F-18 FDG uptake mimicking malignant gastric localizations disappearing after water ingestion on PET/CT images. Clin Nucl Med. 2006;31:835-7.
23. Kamimura K, Fujita S, Nishii R, Wakamatsu H, Nagamachi S, Yano T, et al. An analysis of the physiological FDG uptake in the stomach with the water gastric distention method. Eur J Nucl Med Mol Imaging. 2007;34:1815-8.
24. Bischof Delalove A, Wahl RL. How high a level of FDG abdominal activity is considered normal? J Nucl Med. 1995;36:106P.
25. Kim SK, Kang KW, Roh JW, Sim JS, Lee ES, Park SY. Incidental ovarian 18F-FDG accumulation on PET: correlation with the menstrual cycle. Eur J Nucl Med Mol Imaging. 2005;32:757-63.
26. Nishizawa S, Inubushi M, Okada H. Physiological 18F-FDG uptake in the ovaries and uterus of healthy female volunteers. Eur J Nucl Med Mol Imaging. 2005;32:549-56.
27. Nishizawa S, Inubushi M, Ozawa F, Kido A, Okada H. Physiological FDG uptake in the ovaries after hysterectomy. Ann Nucl Med. 2007;21:345-8.
28. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics. 1999;19:61-77.
29. Reinhardt MJ, Kubota K, Yamada S, Iwata R, Yaegashi H. Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of fluorodeoxyglucose, L-methionine and thymidine. J Nucl Med. 1997;38:280-7.
30. Chang JM, Lee HJ, Goo JM, Lee HY, Lee JJ, Chung JK, et al. False positive and false negative FDG-PET scans in various thoracic diseases. Korean J Radiol. 2006;7:57-69.
31. Von Rohr L, Klaeser B, Joerger M, Kluckert T, Cerny T, Gillessen S. Increased pulmonary FDG uptake in bleomycin-associated pneumonitis. Onkologie. 2007;30:320-3.
32. Ben-Haim S, Kupzov E, Tamir A, Frenkel A, Israel O. Changing patterns of abnormal vascular wall F-18 fluorodeoxyglucose uptake on follow-up PET/CT studies. J Nucl Cardiol. 2006;13:791-800.
33. Veinot JP, Edwards WD. Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. Hum Pathol. 1996;27:766-73.
34. Jingu K, Kaneta T, Nemoto K, Ichinose A, Oikawa M, Takai Y, et al. The utility of 18F-fluorodeoxyglucose positron emission tomography for early diagnosis of radiation-induced myocardial damage. Int J Radiat Oncol Biol Phys. 2006;66:845-51.
35. Bural GG, Kumar R, Mavi A, Alavi A. Reflux esophagitis secondary to chemotherapy detected by serial FDG-PET. Clin Nucl Med. 2005;30:182-3.
36. Chamroonrat W, Posteraro A, El-Haddad G, Zhuang H, Alavi A. Radiation myelopathy visualized as increased FDG uptake on positron emission tomography. Clin Nucl Med. 2005;30:560.
37. Meyer MA, Nathan CO. Reduced F-18 fluorodeoxyglucose uptake within marrow after external beam radiation. Clin Nucl Med. 2000;25:279-80.
38. Kwek BH, Aquino SL, Fischman AJ. Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis. Chest. 2004;125:2356-60.
39. Brink I, Reinhardt MJ, Hoegerle S, Altehoefer C, Moser E, Nitzsche EU. Increased metabolic activity in the thymus gland studied with 18F-FDG PET: age dependency and frequency after chemotherapy. J Nucl Med. 2001;42:591-5.
40. Ozawa T, Okamura T, Harada T, Muraoka M, Ozawa N, Koyama K, et al. Accumulation of glucose in keloids with FDG-PET. Ann Nucl Med. 2006;20:41-4.
41. Festic E, Abraham PJ, Burnett OL, Young PM, Johnson MM. Increased radiotracer uptake on positron emission tomography after invasive thoracic procedures: a case series. Mayo Clin Proc. 2007;82:1060-4.
42. Prosch H, Mirzaei S, Oschatz E, Strasser G, Huber M, Mostbeck G. Case report: Gluteal injection site granulomas: false positive finding on FDG-PET in patients with non-small cell lung cancer. Br J Radiol. 2005;78:758-61.
43. Metser U, Miller E, Lerman H, Even-Sapir E. Benign nonphysiologic lesions with increased 18F-FDG uptake on PET/CT: characterization and incidence. AJR Am J Roentgenol. 2007;189:1203-10.
44. Meyer M, Gast T, Raja S, Hubner K. Increased F-18 FDG accumulation in an acute fracture. Clin Nucl Med. 1994;19:13-4.
45. Ghersin E, Keidar Z, Brook OR, Amendola MA, Engel A. A new pitfall on abdominal PET/CT: a retained surgical sponge. J Comput Assist Tomogr. 2004;28:839-41.
46. García-Barrecheguren E, Rodríguez Fraile M, Toledo Santana G, Valentí Nín JR, Richter Echevarría JA. [FDG-PET: a new diagnostic approach in hip prosthetic replacement] Rev Esp Med Nucl. 2007;26:208-20.
47. Julian A, Payoux P, Rimailho J, Paynot N, Esquerre J. Uterine uptake of F-18 FDG on positron emission tomography induced by an intrauterine device: Unusual pitfall. Clin Nucl Med. 2007;32:128-9.
48. Tatsumi M, Cohade C, Nakamoto Y, Wahl RL. Fluorodeoxyglucose uptake in the aortic wall at PET/CT: possible finding for active atherosclerosis. Radiology. 2003;229:831-7.
49. Kitazono MT, Colletti PM. FDG PET imaging of acute cholecystitis. Clin Nucl Med. 2006;31:23-4.
50. Ak I, Gülbaş Z. Intense F-18 FDG accumulation in stomach in a patient with Hodgkin lymphoma: Helicobacter pylori infection as a pitfall in oncologic diagnosis with F-18 FDG PET imaging. Clin Nucl Med. 2005;30:41.
51. Basu S, Nair N. Intense F-18 FDG uptake in the stomach wall in follicular gastritis in Zollinger-Ellison syndrome. Clin Nucl Med. 2007;32:150-1.
52. Meyer MA. Diffusely increased colonic F-18 FDG uptake in acute enterocolitis. Clin Nucl Med. 1995;20:434-5.
53. Alavi A, Gupta N, Alberini JL, Hickeson M, Adam LE, Bhargava P, et al. Positron emission tomography imaging in nonmalignant thoracic disorders. Semin Nucl Med. 2002;32:293-321.
54. Vesselle HJ, Miraldi FD. FDG PET of the retroperitoneum: normal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls. Radiographics. 1998;18:805-23.
55. Ryan A, McCook B, Sholosh B, Pryma DA, Jablonowski E, Fuhrman C, et al. Acute intramural hematoma of the aorta as a cause of positive FDG PET/CT. Clin Nucl Med. 2007;32:729-31.
56. Lai P, Bomanji JB, Mahmood S, Nagabhushan N, Syed R, Gacinovic S, et al. Detection of tumour thrombus by 18F-FDGPET/CT imaging. Eur J Cancer Prev. 2007;16:90-4.
57. Hany TF, Heuberger J, von Schulthess GK. Iatrogenic FDG foci in the lungs: a pitfall of PET image interpretation. Eur Radiol. 2003;13:2122-7.
58. Peters AM. The use of nuclear medicine in infections. Br J Radiol. 1998;71:252-61.
59. O'Doherty MJ, Barrington SF, Campbell M, Lowe J, Bradbeer CS. PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med. 1997;38:1575-83.
60. Barrington SF, O'Doherty MJ. Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging. 2003;30 Suppl 1:S117-27.
61. Sonet A, Graux C, Nollevaux MC, Krug B, Bosly A, Vander Borght T. Unsuspected FDG-PET findings in the follow-up of patients with lymphoma. Ann Hematol. 2007;86:9-15.
62. Knopp MV, Bischoff HG. Evaluation of pulmonary lesions with positron emission tomography. Radiologe. 1994;34:588-91.
63. Brust D, Polis M, Davey R, Hahn B, Bacharach S, Whatley M, et al. Fluorodeoxyglucose imaging in healthy subjects with HIV infection: impact of disease stage and therapy on pattern of nodal activation. AIDS. 2006;20:495-503.
64. Williams G, Joyce RM, Parker JA. False-positive axillary lymph node on FDG-PET/CT scan resulting from immunization. Clin Nucl Med. 2006;31:731-2.
65. Konishi J, Yamazaki K, Tsukamoto E, Tamaki N, Onodera Y, Otake T, et al. Mediastinal lymph node staging by FDG-PET in patients with non-small cell lung cancer: analysis of false-positive FDG-PET findings. Respiration. 2003;70:500-6.
66. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med. 1994;35:1-3.
67. Chen YK, Wang YF, Chiu JS. Diagnostic trinity: Graves' disease on F-18 FDG PET. Clin Nucl Med. 2007;32:816-7.
68. Chen YK, Chen YL, Cheng RH, Yeh CL, Lee CC, Hsu CH. The significance of FDG uptake in bilateral thyroid glands. Nucl Med Commun. 2007;28:117-22.
69. Karantanis D, Bogsrud TV, Wiseman GA, Mullan BP, Subramaniam RM, Nathan MA, et al. Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland. J Nucl Med. 2007;48:896-901.
70. Lin EC, Helgans R. Adrenal hyperplasia in Cushing's syndrome demonstrated by FDG positron emission tomographic imaging. Clin Nucl Med. 2002;27:516-7.
71. Gratz S, Dörner J, Fischer U, Behr TM, Béhé M, Altenvoerde G, et al. 18F-FDG hybrid PET in patients with suspected spondylitis. Eur J Nucl Med Mol Imaging. 2002;29:516-24.
72. Rosen RS, Fayad L, Wahl RL. Increased 18F-FDG uptake in degenerative disease of the spine: Characterization with 18F-FDG PET/CT. J Nucl Med. 2006;47:1274-80.
73. Cook GJ, Maisey MN, Fogelman I. Fluorine-18-FDG PET in Paget's disease of bone. J Nucl Med. 1997;38:1495-7.
74. Shon IH, Fogelman I. F-18 FDG positron emission tomography and benign fractures. Clin Nucl Med. 2003;28:171-5.
75. Ahn SH, Scheiner JD, Noto RB. Uptake of F-18 FDG by a hiatal hernia. Clin Nucl Med. 2002;27:733-4.
76. Muylle K, Everaert H, De Mey J, Lahoutte T, Franken PR, Bossuyt A. FDG accumulation in inguinal herniation mimicking metastatic disease. Clin Nucl Med. 2004;29:652-3.
77. Beanlands R. Positron emission tomography in cardiovascular disease. Can J Cardiol. 1996;12:875-83.
78. Chang CY, Tsai CS, Peng YJ, Huang WS. Large B-cell lymphoma mimicking ischemic heart disease demonstrated by F-18 fluorodeoxyglucose PET/CT in a heart transplant patient. J Nucl Cardiol. 2007;14:754-7.
79. Fujii H, Ide M, Yasuda S, Takahashi W, Shohtsu A, Kubo A. Increased FDG uptake in the wall of the right atrium in people who participated in a cancer screening program with whole-body PET. Ann Nucl Med. 1999;13:55-9.
80. Ak I, Ozalp S, Yalçin OT, Zor E, Vardareli E. Uptake of 2-[18F] fluoro-2-deoxy-D-glucose in uterine leiomyoma: imaging of four patients by coincidence positron emission tomography. Nucl Med Commun. 2004;25:941-5.
81. Shida M, Murakami M, Tsukada H, Ishiguro Y, Kikuchi K, Yamashita E, et al. F-18 fluorodeoxyglucose uptake in leiomyomatous uterus. Int J Gynecol Cancer. 2007;17:285-90.
82. Burdick MJ, Jolles PR, Grimes MM, Henry DA. Mediastinal hibernoma simulates a malignant lesion on dual time point FDG imaging. Lung Cancer. En prensa 2007.
83. Subramaniam RM, Clayton AC, Karantanis D, Collins DA. Hibernoma: 18F FDG PET/CT imaging. J Thorac Oncol. 2007;2:569-70.
84. Neumann DR, Esselstyn CB, MacIntyre WJ, Chen EQ, Go RT, Kohse LM. Parathyroid adenoma localization by PET FDG. J Comput Assist Tomogr. 1993;17:976-7.
85. Choi JY, Lee KS, Kim HJ, Shim YM, Kwon OJ, Park K, et al. Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization. J Nucl Med. 2006;47:609-15.
86. Jung YS, Kang JG, Park WS, Ryu J. Pilomatricoma: diagnostic pitfalls in PET/CT and fine-needle aspiration biopsy. Otolaryngol Head Neck Surg. 2007;137:845-6.
87. Son JM, Ahn MI, Cho KD, Yoo J, Park YH. Varying degrees of FDG uptake in multiple benign neurofibromas on PET/CT. Br J Radiol. 2007;80:e222-6.
88. Pitman AG, Binns DS, Ciavarella F, Hicks RJ. Inadvertent 2-deoxy-2-[18F]fluoro-D-glucose lymphoscintigraphy: a potential pitfall characterized by hybrid PET-CT. Mol Imaging Biol. 2002;4:276-8.
89. Delbeke D, Martin WH, Patton JA, Sandler MP. Value of iterative reconstruction, attenuation correction, and image fusion in the interpretation of FDG PET images with an integrated dual-head coincidence camera and X-ray-based attenuation maps. Radiology. 2001;218:163-71.
90. Riddell C, Carson RE, Carrasquillo JA, Libutti SK, Danforth DN, Whatley M, et al. Noise reduction in oncology FDG PET images by iterative reconstruction: a quantitative assessment. J Nucl Med. 2001;42:1316-23.
91. Schöder H, Erdi YE, Chao K, Gonen M, Larson SM, Yeung HW. Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients. J Nucl Med. 2004;45:559-66.
92. Razifar P, Sandström M, Schnieder H, Långström B, Maripuu E, Bengtsson E, et al. Noise correlation in PET, CT, SPECT and PET/CT data evaluated using autocorrelation function: a phantom study on data, reconstructed using FBP and OSEM. BMC Med Imaging. 2005;5:5.
93. Valk PE, Bailey DL, Townsend DW, Maisey MN. Positron emission tomography: basic science and clinical practice. London: Springer-Verlag London Ltd; 2003. p. 502.
94. De Wever W, Stroobants S, Verschakelen JA. Integrated PET/CT in lung cancer imaging: history and technical aspects. JBR-BTR. 2007;90:112-9.
95. Bujenovic S, Mannting F, Chakrabarti R, Ladnier D. Artifactual 2-deoxy-2-[(18)F]fluoro-D-glucose localization surrounding metallic objects in a PET/CT scanner using CT-based attenuation correction. Mol Imaging Biol. 2003;5:20-2.
96. Goerres GW, Ziegler SI, Burger C, Berthold T, Von Schulthess GK, Buck A. Artifacts at PET and PET/CT caused by metallic hip prosthetic material. Radiology. 2003;226:577-84.
97. Kamel EM, Burger C, Buck A, von Schulthess GK, Goerres GW. Impact of metallic dental implants on CT-based attenuation correction in a combined PET/CT scanner. Eur Radiol. 2003;13:724-8.
98. Halpern BS, Dahlbom M, Waldherr C, Yap CS, Schiepers C, Silverman DH, et al. Cardiac pacemakers and central venous lines can induce focal artifacts on CT-corrected PET images. J Nucl Med. 2004;45:290-3.
99. Dizendorf E, Hany TF, Buck A, Von Schulthess GK, Burger C. Cause and magnitude of the error induced by oral CT contrast agent in CT-based attenuation correction of PET emission studies. J Nucl Med. 2003;44:732-8.
100. Ay MR, Zaidi H. Assessment of errors caused by X-ray scatter and use of contrast medium when using CT-based attenuation correction in PET. Eur J Nucl Med Mol Imaging. 2006;33:1301-13.
101. Heusner TA, Fronz U, Jentzen W, Verhagen R, Forsting M, Bockisch A, et al. The effect of different chemoembolization materials on CT-based attenuation correction in PET/CT. Rofo. 2007;179:1159-65.
102. Ben-Haim S, Kupzov E, Tamir A, Israel O. Evaluation of 18F-FDG uptake and arterial wall calcifications using 18F-FDG PET/CT. J Nucl Med. 2004;45:1816-21.
103. Cohade C, Whal RL. Applications of PET/CT image fusion in clinical PET: clinical use, interpretation methods, diagnostic improvements. Semin Nucl Med. 2003;33:228-37.
104. Beyer T, Bockisch A, Kühl H, Martinez MJ. Whole-body 18F-FDG PET/CT in the presence of truncation artifacts. J Nucl Med. 2006;47:91-9.
105. Kostakoglu L, Hardoff R, Mirtcheva R, Goldsmith SJ. PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake. Radiographics. 2004;24:1411-31.
106. Vogel WV, van Dalen JA, Schinagl DA, Kaanders JH, Huisman H, Corstens FH, et al. Correction of an image size difference between positron emission tomography (PET) and computed tomography (CT) improves image fusion of dedicated PET and CT. Nucl Med Commun. 2006;27:515-9.
107. Wang J, Cook G, Frank J, Dina R, Livni N, Lynn J, et al. Case report: PET/CT, a cautionary tale. BMC Cancer. 2007;7:147.
108. Nakamoto Y, Chin BB, Cohade C, Osman M, Tatsumi M, Wahl RL. PET/CT: artifacts caused by bowel motion. Nucl Med Commun. 2004;25:221-5.
109. Sarikaya I, Yeung HW, Erdi Y, Larson SM. Respiratory artefact causing malpositioning of liver dome lesion in right lower lung. Clin Nucl Med. 2003;28:943-4.
110. Robinson P, Parkin A. Respiratory motion artefacts on PET/CT. Eur J Nucl Med Mol Imaging. 2003;30:1712.
111. Goerres GW, Kamel E, Seifert B, Burger C, Buck A, Hany TF, et al. Accuracy of image coregistration of pulmonary lesions in patients with non-small cell lung cancer using an integrated PET/CT system. J Nucl Med. 2002;43:1469-75.
112. Osman MM, Cohade C, Nakamoto Y, Marshall LT, Leal JP, Wahl RL. Clinically significant inaccurate localization of lesions with PET/CT: frequency in 300 patients. J Nucl Med. 2003;44:240-3.